



Original article

Comparative study of clinical profile between familial and sporadic Parkinson's disease

Anis Jukkarwala

Department of Neurology, Geetanjali Medical College & Hospital, Udaipur- 313002, Rajasthan, India.

Article history

Received 11 April 2017
Revised 29 April 2017
Accepted 29 April 2017
Early online 20 May 2017
Print 31 July 2017

Corresponding author

Anis Jukkarwala
Assistant Professor,
Department of Neurology,
Geetanjali Medical College &
Hospital, Udaipur- 313002,
Rajasthan, India.
Phone: +91-9001295552
Email: anis_jw@yahoo.com

Abstract

The precise etiology of Parkinson's disease (PD) is unknown and the relative contributions of genetic and environmental factors may vary in different cases. So, the present study was conducted to compare clinical profile and medication dose in familial and sporadic PD. The patients in the present study were recruited from Movement disorders clinic of tertiary care centre after taking approval from the Institutional Ethics Committee and written informed consent from all patients. All patients underwent a detailed clinical examination and age of onset (in years), duration of motor symptom (in years), clinical subtype of PD (tremor vs bradykinesia dominant vs mixed), comorbid illness (diabetes, hypertension), L-dopa equivalent dose, individual PD medications with doses and other medications were noted. Modified Hoehn and Yahr staging was done in both the groups. Mean age of onset of disease was less than 50 years in both the groups. Majority of patients (85%) in both groups had tremor dominant PD. L-dopa dose for both the PD was found effective and there was non-significant difference in their doses. There was no significant difference in the demographic features, clinical characteristics and medication doses between familial and sporadic PD patients. To conclude, there was no significant difference between both the groups for clinical profile and medication used. This may be due the fact that frequency of genetic mutations in PD shows significant variation based on ethnicity which was not found in this Indian study.

Key words: Familial, L-dopa, Parkinson's disease, Sporadic

DOI: 10.5455/jmas.263847

© 2017 Deccan College of Medical Sciences. All rights reserved.

Parkinson's disease (PD) is a common neurodegenerative disorder characterized by resting tremor, rigidity, bradykinesia and postural instability with good response to L-dopa. Dopamine loss is the main pathological feature of PD, and dopamine receptor agonists are the most effective symptomatic PD medication¹. PD is unlikely to be a single disease entity; it represents a

diversity of conditions resulting in a common clinical presentation². The precise etiology of PD is unknown and the relative contributions of genetic and environmental factors may vary in different cases². Those without a positive family history and classic late age of onset are sporadic forms whereas those patients with a positive family history and early age of onset (usually less than 40

years) are classified as familial PD. Approximately 10-15% of patients with the typical clinical picture of PD have a positive family history compatible with a Mendelian (autosomal dominant or autosomal recessive) inheritance³. Mutations within the genes at 6 loci (α -synuclein, LRRK2, Parkin, DJ1, PINK1 and ATP13A2) have conclusively been demonstrated to cause familial parkinsonism⁴⁻⁷. These genes are found in selective ethnic populations and a few of them have atypical clinical features like myoclonus and hypoventilation in α -synuclein⁴, dementia with lewy bodies in E46K substitution of α -synuclein gene⁸ and progressive supranuclear gaze palsy like presentation in ATP13A2 related parkinsonism⁷. One study of specific gene mutations in PD has reinforced the relevance of oxidative stress and mitochondrial dysfunction in the familial and the sporadic forms of PD⁹.

Braak proposed a staging model for the progression of pathological process in PD which starts in the brainstem and progresses in a topographically predictable sequence upto neocortex in last stage¹⁰. Drugs for PD can improve motor functions from their early stages¹¹. On literature search very few studies were found which had compared clinical profile and medication dose for both the types of PD. So, the present study was conducted to compare clinical profile and medication dose in familial and sporadic PD in Indian population.

Material and methods

The present prospective study was conducted in a teaching hospital after taking approval from the Institutional Technical Advisory Committee and the Ethics Committee. The patients were recruited from Movement Disorders clinic of Sree Chitra Tirunal Institute of Medical Sciences and Technology (SCTIMST), Thiruvananthapuram, Kerala. Written informed consent was obtained from all patients prior to enrolment. Parkinson's disease was diagnosed by United Kingdom Parkinson's Disease (UKPD) Society Brain Bank diagnostic criteria¹².

One or more of the family members with a documented diagnosis were included in Familial PD group and no family member with a documented diagnosis of PD (other than proband) in preceding three generations or any successive generation were included in sporadic PD group. Patients with comorbid illness/condition likely to cause sleep dysfunction (like substance abuse, obstructive airway disease, cardiac failure) were excluded from the study.

Familial and sporadic PD patients who participated in the study were interviewed using the structured proforma during their routine clinic visits. All patients underwent a detailed clinical examination and the following parameters were recorded:

- age of onset (in years)
- duration of motor symptom (in years)
- clinical subtype of PD (tremor vs bradykinesia dominant vs mixed)
- comorbid illness (diabetes, hypertension)
- L-dopa equivalent dose, individual PD medications with doses
- other medications

Modified Hoehn and Yahr (H and Y) staging was done for Parkinson's disease in both the groups.

Table 1: Modified Hoehn and Yahr staging

Stage	Disease state
0	No signs of disease
1	Unilateral disease
1.5	Unilateral plus axial involvement
2	Bilateral disease, without impairment of balance
2.5	Mild bilateral disease with recovery on pull test
3	Mild to moderate bilateral disease; some postural instability; physically independent
4	Severe disability; still able to walk or stand unassisted
5	Wheelchair bound or bedridden unless aided

SPSS version 17 was used for data analysis. For categorical variables, percentages were compared by Fisher's exact test. For quantitative variables, Mann-Whitney test was used. p value < 0.05 was considered significant.

Results

A total of 20 cases of Familial and 20 cases of Sporadic PD were finally compared. In the Familial PD group, 12 (60%) patients had single effected family member, 7 (35%) patients had 2 effected family members and 1 (5%) patient had 3 effected family members (other than proband). Majority of patients in both groups had tremor dominant PD. Table 2 shows the classification of patients in both groups depending on clinical subtype.

Table 2: Classification of patients based on predominant clinical manifestation

Subtype	Familial PD n (%)	Sporadic PD n (%)
Tremor dominant	17 (85)	17 (85)
Rigid-bradykinetic	2 (10)	2 (10)
Mixed	1 (5)	1 (5)

Diabetes was found in 25% patients of familial PD and 15% in sporadic PD; whereas hypertension was found in 20% cases of each type of PD. (Table 3)

Table 3: Number of patients with co-morbid illness in each group

Disease	Familial PD n (%)	Sporadic PD n (%)
Diabetes	5 (25)	3 (15)
Hypertension	4 (20)	4 (20)

There was no significant difference in the demographic features, clinical characteristics and medication doses between Familial and Sporadic PD patients. (Table 4)

Table 4: Comparison of demographic features, clinical characteristics and medication doses between Familial and Sporadic PD patients

Clinical feature and medications	Familial PD	Sporadic PD	p value
	Mean \pm SD (n=20)	Mean \pm SD (n=20)	
Age of onset (yrs)	46.8 \pm 10	48.75 \pm 7.9	0.41
Duration of motor symptom (yrs)	6.2 \pm 3.2	7.7 \pm 4	0.3
L-dopa equivalent dose (mg)	447.5 \pm 216.1	589.5 \pm 321.7	0.11
L-dopa daily dose (mg)	227.5 \pm 172	374.7 \pm 245.6	0.035*
Dopamine in L-dopa equivalent dose (mg)	181.7 \pm 172.7	190.5 \pm 172.4	0.86
Rasagiline daily dose (mg)	0.15 \pm 0.36	0 \pm 0	0.42
Trihexyphenidyl daily dose (mg)	1.7 \pm 2.6	1.05 \pm 1.9	0.6
Amantadine daily dose (mg)	15 \pm 67	65 \pm 103.9	0.2
Escitalopram daily dose (mg)	2 \pm 3.4	3.7 \pm 4.8	0.38
Clonazepam daily dose (mg)	0.12 \pm 0.3	0.05 \pm 0.15	0.77
H and Y stage	2.12 \pm 0.5	2.22 \pm 0.44	0.56

*p value \leq 0.05 (significant)

Discussion

Parkinson's disease (PD) is a progressive nervous system disease occurring most often after the age of 50 years and effecting all ethnic groups¹³. Genetic susceptibility plays a stronger role in early onset familial cases, whereas environmental factors play a stronger role for late onset sporadic cases¹⁴. But no other specific clinical signs or symptoms distinguish familial from sporadic cases. This study was conducted to compare the pattern of clinical features and medication dose used in two etiological subtypes of PD - Familial vs Sporadic.

In present study majority of patients (85%) in both groups had tremor dominant PD. Study conducted by Baba et al had also shown tremor dominant PD

in both the groups in which 54% of the patients with familial PD and 48% of those with sporadic PD were reported tremor as initial motor symptoms¹⁵. In the present study no significant difference in initial motor symptoms were found in both the groups. Similar non-significant difference was also reported by Baba et al which explains that it may be due to the similar involvement of nigrostriatal lesion in either type of PD¹⁵.

Diabetes and hypertension were the most common comorbid illnesses seen in both group of patients in present study. One study has shown that PD patients had diabetes mellitus (DM) and heart diseases as frequently as in the general population and these illnesses are common irrespective of gender or race¹⁶. Many studies suggest the asso-

ciation of DM with PD because both are age-related chronic diseases and share remarkably similar pathways of mitochondrial dysfunction^{17,18}.

Mean age of onset of disease was less than 50 years of age in both the groups and duration of disease was also less than 8 years in both the groups. H and Y stage also showed mean value around 2 in both groups. This shows that in present study; both the groups disease is in early stage because the peak age of onset of PD is in the early 60s (range 35-85 years), and the course of illness ranges from 10 to 25 years¹⁹. At the beginning of the illness or as the disease progresses, postural instability and falls manifest, which adds to the disability and severity of the illness^{13,20}. L-dopa dose for both the PD was found effective and there was no difference in their doses. Similar L-dopa responsive Familial PD as compared to Sporadic PD was also found in other studies^{15,21,22}. Drugs are most widely used treatment for insomnia in clinical practice for PD and these sleep disturbances may be related to factors such as depression²³. In a survey of patients with PD living in the community, 40% were found to be using sleeping pills, compared to 23% of the non-PD controls²⁴. Similarly in our study clonazepam and escitoparm were given to both the groups. There was no significant difference between the two groups with respect to age of onset, disease duration, clinical subtype, disease severity, comorbid illness, levodopa equivalent dose and other non-PD medications. Previous studies highlighted the importance of all above mentioned factors in motor disturbances²⁵. Though the mean L-dopa daily dose was lower in Familial PD patients, there was no significant difference in L-dopa equivalent dose between the two groups indicating no significant difference in the total dose of dopaminergic medications.

Madegowda et al reported Parkin gene mutations in 2 out of 20 cases of familial early onset PD from South India²⁶. Punia et al did LRRK2 mutation testing in 1012 Indian PD patients and found a heterozygous G2019S mutation in a single young PD patient²⁷. Another recent study from South India testing for LRRK2 G2019S mutation in 86 familial PD cases did not find even a single case positive for the mutation. These studies suggest that the frequency of genetic mutations in PD shows significant variation based on ethnicity²⁸. This could be the reason that we could not find significant difference for clinical features and treatment between both the groups in our study. Similar results were found in Papapetropoulos et study which was conducted in Greece²⁹.

Conclusion

We conclude that we could not find significant difference between both the groups for clinical profile or motor symptoms and dose of medications used. This may be due to the fact that frequency of genetic mutations in PD shows significant variation based on ethnicity which was not found in this Indian study. In our study we compare mainly motor symptoms of PD. However larger studies are needed to compare both motor as well as non-motor symptoms of both the types of PD.

Acknowledgments: None

Conflict of interest: None

References

1. Smith Y, Wichmann T, Factor SA, DeLong MR. Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa. *Neuropsychopharmacology* 2012 Jan; 37(1):213-46.
2. Weiner WJ. There is no Parkinson disease. *Arch Neurol*. 2008 Jun; 65(6):705-8.
3. Gasser T. Update on the genetics of Parkinson's disease. *Mov Disord* 2007 Sep; 22 Suppl 17:S343-50.
4. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL. Mutation in the alpha synuclein gene identified in families with Parkinson's disease. *Science* 1997 Jun 27; 276(5321):2045-7.
5. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, López de Munain A, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, de Silva R, Lees A, Martí-Massó JF, Pérez-Tur J, Wood NW, Singleton AB. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. *Neuron* 2004 Nov; 44(4): 595-600.
6. Noyce AJ, Lees AJ, Schrag AE. The prediagnostic phase of Parkinson's disease. *J Neurol Neurosurg Psychiatry* 2016 Aug; 87(8):871-8.
7. Ramirez A, Heimbach A, Grundemann J, Stiller B, Hampshire D, Cid LP, Goebel I, Mubaidin AF, Wriekat AL, Roepner J, Al-Din A, Hillmer AM, Karsak M, Liss B, Woods CG, Behrens MI, Kubisch C. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. *Nat Genet* 2006 Oct; 38(10):1184-91.
8. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atarés B, Llorens V, Gomez Tortosa E, del Ser T, Muñoz DG, de Yébenes JG. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. *Ann Neurol*. 2004 Feb; 55(2):164-73.
9. Schapira AH. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. *Lancet Neurol* 2008 Jan; 7(1):97-109.
10. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. *Neurobiol Aging* 2003 Mar-Apr; 24(2):197-211.
11. Abe K. Non-motor signs and symptoms in Parkinson's disease. *Health* 2012 Nov; 4(11):1133-7.
12. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a

- clinico-pathological study of 100 cases. *J Neurol Neurosurg Psychiatry* 1992 Mar; 55(3):181-4.
13. Bruin VM, Bittencourt LR, Tufik S. Sleep-wake disturbances in Parkinson's disease: current evidence regarding diagnostic and therapeutic decisions. *Eur Neurol*. 2012; 67(5):257-67.
 14. Elbaz A, Clavel J, Rathouz PJ, Moisan F, Galanaud JP, Delemotte B, Alperovitch A, Tzourio C. Professional exposure to pesticides and Parkinson disease. *Ann Neurol*. 2009 Oct; 66(4):494-504.
 15. Baba Y, Markopoulou K, Putzke JD, Whaley NR, Farrer MJ, Wszolek ZK, Uitti RJ. Phenotypic commonalities in familial and sporadic Parkinson disease. *Arch Neurol*. 2006 Apr; 63(4):579-83.
 16. Gorell JM, Johnson CC, Rybicki BA. Parkinson's disease and its comorbid disorders: An analysis of Michigan mortality data, 1970 to 1990. *Neurology* 1994 Oct; 44(10):1865-8.
 17. Sun Y, Chang YH, Chen HF, Su YH, Su HF, Li CY. Risk of Parkinson disease onset in patients with diabetes: a 9-year population-based cohort study with age and sex stratifications. *Diabetes Care* 2012 May; 35(5):1047-9.
 18. Santiago JA, Potashkin JA. Shared dysregulated pathways lead to Parkinson's disease and diabetes. *Trends Mol Med*. 2013 Mar; 19(3):176-86.
 19. Mehndiratta M, Garg RK, Pandey S. Nonmotor symptom complex of Parkinson's disease - an under-recognized entity. *J Assoc Physicians India*. 2011 May; 59:302-8, 313.
 20. Poewe W. The natural history of Parkinson's disease. *J Neurol*. 2006 Dec; 253 Suppl 7:VII2-6.
 21. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Müller-Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T. Mutations in LRRK2 cause autosomal dominant parkinsonism with pleomorphic pathology. *Neuron*. 2004 Nov 18; 44(4):601-7.
 22. Pankratz N, Nichols WC, Uniacke SK, Halter C, Murrel J, Rudolph A, Shults CW, Conneally PM, Foroud T, Parkinson Study Group. Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families. *Hum Mol Genet*. 2003 Oct 15; 12(20):2599-608.
 23. Kupfer DJ, Reynolds CF 3rd. Management of insomnia. *N Engl J Med* 1997 Jan 30; 336(5):341-6.
 24. Tandberg E, Larsen JP, Karlsen K. A community-based study of sleep disorders in patients with Parkinson's disease. *Mov Disord*. 1998 Nov; 13(6):895-9.
 25. Kumar S, Bhatia M, Behari M. Sleep disorders in Parkinson's disease. *Mov Disord*. 2002 Jul; 17(4):775-81.
 26. Madegowda RH, Kishore A, Anand A. Mutational screening of the parkin gene among South Indians with early onset Parkinson's disease. *J Neurol Neurosurg Psychiatry*. 2005 Nov; 76(11):1588-90.
 27. Punia S, Behari M, Govindappa ST, Swaminath PV, Jayaram S, Goyal V, Muthane UB, Juyal RC, Thelma BK. Absence/rarity of commonly reported LRRK2 mutations in Indian Parkinson's disease patients. *Neurosci Lett* 2006 Dec 1; 409(2):83-8.
 28. Vijayan B, Gopala S, Kishore A. LRRK2 G2019S mutation does not contribute to Parkinson's disease in South India. *Neurol India* 2011 Mar-Apr; 59(2):157-60.
 29. Papapetropoulos S, Paschalis C, Athanassiadou A, Papadimitriou A, Ellul J, Polymeropoulos MH, Papapetropoulos T. Clinical phenotype in patients with α -synuclein Parkinson's disease living in Greece in comparison with patients with sporadic Parkinson's disease. *J Neurol Neurosurg Psychiatry* 2001; 70(5):662-5.